Abstract:Background Hemophilia A (HA) is an inherited bleeding disorder caused by a deficiency or defect in factor VIII (FVIII). Methods We investigated the role of clot waveform analysis (CWA) of activated partial thromboplastin time in the diagnosis and therapeutic monitoring of HA. The changes in CWA parameters the maximum clotting velocity (|Min1|), maximum clotting acceleration (|Min2|), and maximum clotting deceleration (|Max2|) were detected among mild, moderate, and severe HA groups. Results As the severity of HA subtypes increased, the levels of |Min1|, |Min2|, and |Max2| progressively decreased ( p < 0.05). Receiver operating characteristic curve analysis showed that |Max2| and |Min2| were more effective than |Min1| in distinguishing different types of HA patients, with higher diagnostic efficacy. The standard curves based on Actin FSL reagent for normal and low levels of FVIII:C-|Max2| were established, with R2 values of 0.98 and 0.99, respectively. These curves can be utilized for monitoring during replacement therapies involving full-length recombinant FVIII and B-domain-deleted FVIII. Thirty cases of HA patients utilized the FVIII-|Max2| standard curve to obtain individual pharmacokinetics characteristic parameters. The clearance, half-life (t 1/2 ), time to FVIII:C of 1% above baseline (tt1%), and predicted dosage showed no statistically significant differences compared with one-stage assay ( p > 0.05). Conclusion CWA is an economical and practical tool, and its related parameters are associated with the severity of HA. It has promising clinical prospects in predicting FVIII:C levels and individualized treatment when HA patients undergo replacement therapy. Ethical approval was obtained from Nanjing Drum Tower Hospital Medical Ethics Committee (approval number 2022-360-03). Written informed consent was obtained from all the patients. All procedures were conducted in accordance with the ethical principles of the Declaration of Helsinki. M.X., G.S., Y.W. designed the experiments, analyzed data, and wrote the paper. G.S. and Y.W. performed the experiments. L.Z. helped with the experiments. * These authors contributed equally to this work. Received: 06 September 2023 Accepted: 15 March 2024 Article published online: 16 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Use of recombinant human coagulation factor viii ( advate ) to treat haemophilia a

Efficacy and Safety of Third-Generation Full Length Recombinant Human Coagulation Factor VIII in the Standard Prophylactic Treatment of Childhood Patients with Moderate-to-Severe Hemophilia A: A Single Center Experience

Coagulation Factor VIII: Biological Basis of Emerging Hemophilia A Therapies

Long-term correction of hemorrhagic diathesis in hemophilia A mice by an AAV-delivered hybrid FVIII composed of the human heavy chain and the rat light chain

Gene Therapy for Hemophilia B Mediated by Recombinant Adeno-Associated Viral Vector with Hfixr338a,a High Catalytic Activity Mutation of Human Coagulation Factor IX

Recombinant factor IX Fc for the treatment of hemophilia B

Combination of FVIII and Low-Dose Rfviia Improves Haemostasis in Acquired Haemophilia A Patients: a Collaborative Controlled Study.

Activated factor X delivered by adeno-associated virus significantly inhibited bleeding and alleviated hemophilic synovitis in hemophilic mice

Evaluation of safety and inhibitor development of recombinant factor Ⅷ treatment in hemophilia A patients:a retrospective nationwide multicenter analysis in China

Factor Replacement Treatment for Hemophilia A: Achievements and Perspectives

A Rare Case of Hemophilia: Acquired Factor VIII Deficiency

Pharmacokinetic evaluation of efanesoctocog alfa: breakthrough factor VIII therapy for hemophilia A

Efficacy and safety of recombinant porcine factor VIII in Japanese patients with acquired hemophilia A

Bioengineering Hemophilia A-specific Microvascular Grafts for Delivery of Full-Length Factor VIII into the Bloodstream

Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders

Enhanced factor VIII heavy chain for gene therapy of hemophilia A.

The Role of Clot Waveform Analysis and Related Parameters in the Diagnosis and Treatment of Hemophilia A

Real-world use of recombinant porcine sequence factor VIII in the treatment of acquired hemophilia A: EU PASS

Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment

Diagnosis and laboratory monitoring of hemophilia A

Prophylactic Treatment of Children with Hemophilia in Sweden